© 2026 GlobalCapital, Derivia Intelligence Limited, company number 15235970, 4 Bouverie Street, London, EC4Y 8AX. Part of the Delinian group. All rights reserved.

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement | Event Participant Terms & Conditions

Health and Biotech

Top Section/Ad

Top Section/Ad

Most recent


Calendar quirk could keep issuance going in December
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
More articles/Ad

More articles/Ad

More articles

  • SSA
    Both the European Commission and the European Court of Justice have put out statements dismissing the verdict of Germany's Federal Constitutional Court (BVG) on the European Central Bank’s Public Sector Purchase Programme, going some way to soothe concerns over the ECB’s future.
  • Eni saw chunky demand for the first Italian corporate bond sold since the coronavirus pandemic hit markets in March, but it had to pay up over its curve compered to oil industry peers from outside Italy.
  • Activity in the high grade European loan market is tailing off, as the initial rush of borrowers securing crisis funding has begun to die down, according to lenders.
  • Equity bankers expect to be busy with more capital raising in the next few weeks as UK corporates prepare for a prolonged period of business interruption after the government laid out plans for a slower reopening of the economy than many had hoped for.
  • European airlines are expected to turn to the equity capital markets soon for financing if they have no recourse to state aid, mirroring their peers on the other side of the Atlantic.
  • With leveraged companies largely shut out of central bank bond buying and price support schemes, sponsors are mulling government-backed lending schemes in several European countries, as they seek to show other creditors that they have abundant access to liquidity. But the schemes often come with strings attached, which could do nearly as much damage to a sponsor's investment thesis as a restructuring.